Wave Life Sciences Ltd.
WVENasdaq
$5.82
↑ +2.6%Jul 17 close · end-of-day
Price
1Y↓ -25.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.2B
Enterprise Value
$620.4M
P/E
—
P/S
—
P/B
2.3
EV/EBITDA
—
PEG
—
FCF Yield
-15.9%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$183.6M
Free Cash Flow (TTM)
-$185.0M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-35.9%
ROIC
—
Debt / Equity
—
Net Cash
$544.6M
Return 1Y
-27.3%
Company profile
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia. It focuses on developing GalNAc-conjugated AIMers to treat hepatic indications.
- CEO
- Paul B. Bolno
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 240
- Headquarters
- Massachusetts
- Website
- wavelifesciences.com
Earnings
WVE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$38.2M↑ +316.9%
Diluted EPS-$0.13↓ -55.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $20.1M | $41.0M | $3.6M | $113.3M | $108.3M | $42.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$153.4M | -$127.0M | -$162.7M | -$68.0M | -$110.4M | -$215.4M |
| Net income | -$149.9M | -$122.2M | -$161.8M | -$57.5M | -$97.0M | -$204.4M |
| Diluted EPS | — | -$2.36 | -$2.05 | -$0.54 | -$0.70 | -$1.21 |
| Operating cash flow | -$116.0M | -$89.0M | -$127.8M | -$19.4M | -$151.0M | -$187.5M |
| Free cash flow | -$117.3M | -$89.6M | -$129.1M | -$20.5M | -$152.0M | -$188.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -763.9% | -310.1% | -4459.3% | -60.0% | -101.9% | -504.1% |
| Net margin | -746.7% | -298.4% | -4434.7% | -50.8% | -89.6% | -478.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.7M | — | — | $9.2M | $8.7M | — | — | $38.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$35.0M | -$63.9M | $23.0M | -$49.8M | -$52.8M | -$56.4M | -$56.5M | -$31.3M |
| Net income | -$32.9M | -$61.8M | $29.3M | -$46.9M | -$50.5M | -$53.9M | -$53.2M | -$26.1M |
| Diluted EPS | -$0.25 | -$0.47 | $0.26 | -$0.29 | -$0.31 | -$0.32 | -$0.29 | -$0.13 |
| Operating cash flow | -$27.5M | -$46.5M | -$43.6M | -$63.0M | -$46.0M | -$44.7M | -$33.8M | -$59.6M |
| Free cash flow | -$27.5M | -$46.9M | -$43.7M | -$63.2M | -$46.3M | -$44.9M | -$33.8M | -$60.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -177.7% | — | — | -542.8% | -606.5% | — | — | -81.8% |
| Net margin | -167.2% | — | — | -510.9% | -580.2% | — | — | -68.2% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.